Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment

Current Opinion in Oncology

Volumn 12, Issue 5, 2000, Pages 466-473

  Cornelison, Terri L ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; CAPSID PROTEIN L2; DNA VACCINE; GENE PRODUCT; NEUTRALIZING ANTIBODY; PROTEIN E7; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS E7 PEPTIDE VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

ANTIBODY PRODUCTION; CHIMERA; CLINICAL TRIAL; FEMALE; GENE EXPRESSION; HUMAN; INCIDENCE; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VIRUS GENE; VIRUS PARTICLE; VIRUS STRAIN; WART VIRUS; WART VIRUS TYPE 16;

FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VIRAL VACCINES;

EID: 0034458262     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200009000-00014     Document Type: Review

References (50)

1. Human papillomavirus vaccines for cervical cancer
2. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden
3. Advances in the diagnosis and treatment of human papillomavirus infections
4. Induction of HPV 16 capsid protein-specific human T cell responses by virus-like particles
5. Identification of the alpha 6 integrin as a candidate receptor for papillomaviruses
6. Chimeric papillomavirus-like particles
7. Papillomaviruses in human cancers
8. Basic biology and biochemistry of gynecologic cancer
9. Human papillomaviruses and cervical neopiasia: A model for carcinogenesis
10. Immunotherapeutic strategies for cervical squamous carcinoma
11. Yohei Ito memorial lecture: Papillomaviruses in human cancers
12. Nasal immunization of mice and human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
13. Human papillomavirus typing and the reduction of cervical cancer risk
14. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
15. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions
16. Control of the cell cycle
17. D-type cyclins
18. G1 phase progression: Cycling on cue
19. Negative regulation of cell growth by TGFβ
20. Review: Mutation of cell cycle regulators; biological and clinical implications for human neoplasia
21. Human papillomavirus and urological tumours: I. Basic science and role in penile cancer
22. Serine/threonine kinase receptors: Mediators of transforming growth factor beta family signals
23. Immortalization and transformation of human cells by human papillomavirus
24. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype
25. Evolution of in vitro transformation and tumorigenesis of HPV-16 and HPV-18 immortalized primary cervical epithelial cells
26. Structure and transcription of human papillomavirus type 18 and 16 sequences in cervical carcinoma cells
27. Therapeutic uterine-cervix cancer vaccines in humans
28. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
29. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras
30. Inhibition of tumorigenicity by cervical cancer cells in nude mice by HPV 18, E6-E7 antisense RNA
31. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: Consequences for the phenotype and E6-p53 and E7-pRB interactions
32. Toward a human papillomavirus vaccine
33. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
34. The new vaccines: Building viruses that elicit antitumor immunity
35. Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I - II trial
36. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16
37. L1-specific protection from tumor challenge elicited by HPV 16 virus-like particles
38. Papillomaviruses: Prophylactic vaccine prospects
39. Papillomavirus-like particle vaccines for cervical cancer
40. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles
41. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine
42. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice
43. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
44. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
45. DNA vaccine against oncogenic hamster cells transformed by HPV 16 E6/E7 oncogenes and the activated ras oncogene
46. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic Tlymphocyte induction and antitumor activity
47. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing routine tumor metastases in the liver and lungs
48. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7
49. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX
50. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity